Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  I like the insights gained from Bioscience Valuation's thorough assessments that allow me to support my decisions with well-founded, rational arguments.

Dr. Axel Wiest, COO R&D, Merck-Serono

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - R&D Risk Analysis

Bioscience Valuation's Assessment of R&D Strategy and Development Risk includes
  • R&D risk evaluation and comparison with benchmarks,
  • fine-tuning of R&D success probabilities
    based on
    - stage of development,
    - indication,
    - degree of innovation,
    - mode of action,
    - type of molecule,
  • optimization of the development plan using decision trees, comparison with alternative
    development scenarios,
  • calculation of expected value jumps once development milestones have been reached,
  • applying the 'value of perfect information' algorithm to inform investment decisions.
Core Services - R&D Productivity Increase

About 50% of all medical research findings may lead to wrong scientific conclusions, thus significantly contributing to preclinical & clinical attrition rates.


Source: Bioscience Valuation Analysis, based on Ioannidis (2005),
The Economist (2013)


R&D productivity can be increased by

  • comprehensive target validation,
  • enhanced statistical power of
    preclinical research,
  • improved clinical trial funding,
  • risk-sharing agreements,
  • optimization of clinical study design,
  • considering insights gained from real world evidence (e.g., patient reported outcomes),
  • engagement in personalized medicine.

Case:
A 'top 15' pharmaceutical company wishes to advance forecasting of resources, considering R&D attriton rates by indication and various other variables.

Bioscience Valuation implemented a stepwise adjustment taking advantage of benchmark attrition rates that allows a more detailed resource planning, with improved capacity utilization.